Open AccessInjury-Dependent Retention of Intraportally Administered Mesenchymal Stromal Cells Following Partial Hepatectomy of Steatotic Liver Does Not Lead to Improved Liver Recovery
Author(s) -
Nele Boeykens,
Peter Ponsaerts,
Annemie Van der Linden,
Zwi Berneman,
Dirk Ysebaert,
Kathleen E. De Greef
Publication year - 2013
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0069092
Subject(s) - mesenchymal stem cell , liver regeneration , liver function , endocrinology , medicine , stromal cell , bone marrow , liver injury , hepatectomy , in vivo , liver function tests , regeneration (biology) , pathology , biology , surgery , microbiology and biotechnology , resection
The aim of this study was to evaluate the effect of bone marrow-derived mesenchymal stromal cell (BM-MSC) administration on liver function following partial hepatectomy (PHx) of methionine/choline-deficient (MCD) diet induced steatotic livers in rodents. Here we identified and validated serum cholinesterase (CHE) and triglyceride (TG) levels as non-invasive markers to longitudinally monitor rat liver function. Using in vivo bioluminescence imaging, retention of BM-MSC in the liver was observed following intraportal administration, but not after intravenous administration. Therefore, BM-MSC were intraportally delivered to investigate the effect on liver recovery and/or regeneration after PHx. However, despite recovery to normal body weight, liver weight and NAS score, both serum CHE and TG levels of non-treated and cell-treated rats with PHx after MCD diet remained significantly lower as compared to those of control rats. Importantly, serum CHE levels, but not TG levels, of cell-treated rats remained significantly lower as compared to those of non-treated rats, thereby warranting that certain caution should be considered for future clinical application of IP BM-MSC administration in order to promote liver regeneration and/or function.